Document Detail


Persistent generation of thrombin after acute myocardial infarction.
MedLine Citation:
PMID:  1576116     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
During the acute phase of myocardial infarction, the generation of thrombin is reflected in the sudden rise of fibrinopeptide A (FPA) and the thrombin-antithrombin III (TAT) complex in blood. We have systematically determined the FPA and TAT plasma concentrations over a period of 14 days after acute myocardial infarction in 100 patients. Mean levels of both thrombin markers were the highest on admission, remained elevated over the following few days, and then gradually declined after day 5. Still, by the end of the first week two thirds of the patients had distinctly elevated TAT and FPA levels, and by the end of the second week such an abnormality was present in half of them. Continuous intravenous heparin infusion at a dose of 20,000 units/day, administered for 1 week to patients who had either received (n = 21) or not received (n = 17) streptokinase, led to a significant depression (p less than 0.05) of thrombin markers over the first 48 hours, an effect that did not persist over the subsequent days of treatment. In patients not assigned to heparin treatment, those in heart failure had significantly (p less than 0.05) higher mean TAT and FPA values on days 3, 5, and 7 compared with patients in whom heart failure was absent. Infarct extension, pulmonary embolism, and death were also associated with a rise in one or both thrombin markers, often preceding the onset of clinical symptoms. Thrombinogenesis was not accompanied by changes in mean plasma concentrations of prothrombin, antithrombin III, or alpha 2-macroglobulin.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
A Szczeklik; J Dropinski; J Radwan; M Krzanowski
Related Documents :
11253856 - Clinical use of new antithrombotic therapies for medical management of acute coronary s...
9007666 - Effect of methylprednisolone on complement activation during heparin neutralization.
20660806 - First clinical application of an actively reversible direct factor ixa inhibitor as an ...
18226876 - Do patients with acute myocardial infarction benefit from treatment with clopidogrel?
17587706 - Quantitative gated single-photon emission computed tomography with (99m)tc sestamibi pr...
1810686 - Diffuse embolization following percutaneous transluminal coronary angioplasty of occlud...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association     Volume:  12     ISSN:  1049-8834     ISO Abbreviation:  Arterioscler. Thromb.     Publication Date:  1992 May 
Date Detail:
Created Date:  1992-06-08     Completed Date:  1992-06-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9101388     Medline TA:  Arterioscler Thromb     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  548-53     Citation Subset:  IM    
Affiliation:
Department of Medicine, Copernicus Academy of Medicine, Kraków, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antithrombin III / analysis*
Female
Fibrinopeptide A / analysis*
Heparin / therapeutic use
Humans
Male
Middle Aged
Myocardial Infarction / blood*,  drug therapy
Peptide Hydrolases / analysis*
Streptokinase / therapeutic use
Thrombin / biosynthesis*
Chemical
Reg. No./Substance:
0/antithrombin III-protease complex; 25422-31-5/Fibrinopeptide A; 9000-94-6/Antithrombin III; 9005-49-6/Heparin; EC 3.4.-/Peptide Hydrolases; EC 3.4.-/Streptokinase; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An imported human case of hookworm infection with worms in the rectum
Next Document:  Supplementation with vitamin E but not beta-carotene in vivo protects low density lipoprotein from l...